Waxman Asks FDA Not To Issue Guidance On Off-Label Promotion
This article was originally published in The Gray Sheet
Executive Summary
Rep. Henry Waxman, chair of the House Committee on Oversight and Government Reform, is urging FDA not to go forward with a guidance that he says would allow companies to use journal articles to promote off-label uses of devices and drugs
You may also be interested in...
FDA Issues Guidance On Off-Label Info; Waxman Seeks ‘Re-examination’
The guidance supports long-standing policy on scientifically sound journal articles and imparts no new freedoms, device industry organization AdvaMed says.
FDA Issues Guidance On Off-Label Info; Waxman Seeks ‘Re-examination’
Rep. Henry Waxman is calling for the Obama administration to re-examine a final FDA guidance that gives companies a way to distribute journal articles discussing off-label uses for approved medical devices and drugs
FDA Issues Guidance On Off-Label Info; Waxman Seeks ‘Re-examination’
Rep. Henry Waxman is calling for the Obama administration to re-examine a final FDA guidance that gives companies a way to distribute journal articles discussing off-label uses for approved medical devices and drugs